Evidence map›Paper›PMID 42761627›Full record

ArticleInternational journal of general medicine2026

Serum HMGB3 and PCSK9 Levels as Predictors of Early Treatment Response in Pediatric

Huan Gao, Yanqin Yu, Dongmei Lyu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Huan Gao *Department of Pediatrics, Shijiazhuang Maternal and Child Health Hospital, Shijiazhuang, Hebei, 050000, People's Republic of China.
Yanqin Yu *Department of Pediatrics, Shijiazhuang Maternal and Child Health Hospital, Shijiazhuang, Hebei, 050000, People's Republic of China.
Dongmei LyuDepartment of Pediatrics, Shijiazhuang Maternal and Child Health Hospital, Shijiazhuang, Hebei, 050000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the predictive value of serum high mobility group box 3 (HMGB3) and proprotein convertase subtilisin/kexin type 9 (PCSK9) levels for poor early treatment response in pediatric Methods: A total of 400 pediatric patients with Results: Serum HMGB3 and PCSK9 levels in children with MPP were significantly higher than those in the healthy control group, and were significantly higher in the poor early treatment response group than in the good early treatment response group (all Conclusion: Serum HMGB3 and PCSK9 are independent predictors of poor early treatment response in children with MPP. Combined detection demonstrates superior predictive performance compared with individual markers and may serve as a reference for short-term risk assessment.

Indexed as

biomarkerschildrenearly treatment responsehigh mobility group box 3Mycoplasma pneumoniae pneumoniaproprotein convertase subtilisin/kexin type 9

Identifiers

PMID42761627
PMCPMC13588128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.